Skip to main content

Table 1 Patient characteristics of both marker discovery and validation studies

From: DNA methylation epigenotypes in breast cancer molecular subtypes

  

Type

  

Basal

ERBB2+

Luminal B

Luminal A

Number of patients

 

59

49

54

53

Age (years)

     
 

Mean

56.1

57.1

56.9

62.9

 

Median

53

57.5

51

61

 

Range (95% CI)

51.5-60.7

52.5-61.6

51.8-61.7

56.9-68.7

Tumor size (cm)

     
 

Mean

2.4

2.8

3.2

3.1

 

Range (95% CI)

2.1-2.7

2.1-3.5

2.5-3.5

2.4-3.7

Histologic grade (%)

     
 

I

5.0

0.0

0.0

6.0

 

II

47.1

24

40.0

55.5

 

III

48.9

76

60.0

38.5

Nodal involvement (%)

     
 

Positive

35.5

63.4

72.2

57.3

 

Negative

64.4

36.6

27.8

42.7

Ki-67 overexpression (%)

     
 

<10%

0.0

8.9

21.9

27.8

 

10%-25%

0.0

36.1

31.2

66.7

 

>25%

100.0

56.0

46.9

5.6

p53 mutation (%)

     
 

Positive

47.2

44.1

21.8

14.8

 

Negative

52.8

55.9

88.2

85.2